Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas. more
Time Frame | LXRX | Sector | S&P500 |
---|---|---|---|
1-Week Return | -11.8% | -2.12% | -3% |
1-Month Return | -11.48% | -3.42% | -0.73% |
3-Month Return | -56.95% | -11.13% | 2.87% |
6-Month Return | -59.16% | -5.74% | 7.17% |
1-Year Return | -41.42% | 3.97% | 25.31% |
3-Year Return | -81.72% | 1.05% | 28.38% |
5-Year Return | -83.79% | 34.37% | 81.89% |
10-Year Return | -88.7% | 97.88% | 183.27% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 322.07M | 24.00M | 298.00K | 139.00K | 1.20M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":7.45,"profit":true},{"date":"2021-12-31","value":0.09,"profit":true},{"date":"2022-12-31","value":0.04,"profit":true},{"date":"2023-12-31","value":0.37,"profit":true}] |
Cost of Revenue | 3.23M | 1.93M | 55.05M | 427.00K | 85.00K | [{"date":"2019-12-31","value":5.87,"profit":true},{"date":"2020-12-31","value":3.5,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":0.78,"profit":true},{"date":"2023-12-31","value":0.15,"profit":true}] |
Gross Profit | 318.84M | 22.07M | (54.75M) | (288.00K) | 1.12M | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":6.92,"profit":true},{"date":"2021-12-31","value":-17.17,"profit":false},{"date":"2022-12-31","value":-0.09,"profit":false},{"date":"2023-12-31","value":0.35,"profit":true}] |
Gross Margin | 99.00% | 91.96% | (18371.81%) | (207.19%) | 92.94% | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":92.89,"profit":true},{"date":"2021-12-31","value":-18557.98,"profit":false},{"date":"2022-12-31","value":-209.29,"profit":false},{"date":"2023-12-31","value":93.88,"profit":true}] |
Operating Expenses | 148.76M | 200.85M | 87.39M | 100.90M | 172.87M | [{"date":"2019-12-31","value":74.06,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":43.51,"profit":true},{"date":"2022-12-31","value":50.24,"profit":true},{"date":"2023-12-31","value":86.07,"profit":true}] |
Operating Income | 141.44M | (178.78M) | (87.09M) | (100.76M) | (171.75M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-126.4,"profit":false},{"date":"2021-12-31","value":-61.57,"profit":false},{"date":"2022-12-31","value":-71.24,"profit":false},{"date":"2023-12-31","value":-121.43,"profit":false}] |
Total Non-Operating Income/Expense | (34.65M) | (22.55M) | (1.34M) | (2.37M) | (7.93M) | [{"date":"2019-12-31","value":-3465200000,"profit":false},{"date":"2020-12-31","value":-2255100000,"profit":false},{"date":"2021-12-31","value":-133600000,"profit":false},{"date":"2022-12-31","value":-236800000,"profit":false},{"date":"2023-12-31","value":-793500000,"profit":false}] |
Pre-Tax Income | 124.12M | (58.57M) | (87.76M) | (101.94M) | (177.12M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-47.19,"profit":false},{"date":"2021-12-31","value":-70.7,"profit":false},{"date":"2022-12-31","value":-82.13,"profit":false},{"date":"2023-12-31","value":-142.7,"profit":false}] |
Income Taxes | (6.01M) | 11.61M | 510.00K | 1.18M | 386.11K | [{"date":"2019-12-31","value":-51.8,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.39,"profit":true},{"date":"2022-12-31","value":10.2,"profit":true},{"date":"2023-12-31","value":3.33,"profit":true}] |
Income After Taxes | 130.13M | (70.18M) | (88.27M) | (103.13M) | (177.51M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-53.93,"profit":false},{"date":"2021-12-31","value":-67.83,"profit":false},{"date":"2022-12-31","value":-79.25,"profit":false},{"date":"2023-12-31","value":-136.4,"profit":false}] |
Income From Continuous Operations | 130.13M | (58.57M) | (87.76M) | (101.94M) | (157.86M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-45.01,"profit":false},{"date":"2021-12-31","value":-67.44,"profit":false},{"date":"2022-12-31","value":-78.34,"profit":false},{"date":"2023-12-31","value":-121.3,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | 130.13M | (70.18M) | (88.27M) | (103.13M) | (177.12M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-53.93,"profit":false},{"date":"2021-12-31","value":-67.83,"profit":false},{"date":"2022-12-31","value":-79.25,"profit":false},{"date":"2023-12-31","value":-136.11,"profit":false}] |
EPS (Diluted) | 1.20 | (0.60) | (0.61) | (0.61) | (0.80) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-50,"profit":false},{"date":"2021-12-31","value":-50.83,"profit":false},{"date":"2022-12-31","value":-50.83,"profit":false},{"date":"2023-12-31","value":-66.67,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
LXRX | |
---|---|
Cash Ratio | 7.17 |
Current Ratio | 7.45 |
Quick Ratio | 7.43 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
LXRX | |
---|---|
ROA (LTM) | -44.16% |
ROE (LTM) | -136.09% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
LXRX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.44 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.56 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
LXRX | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 50.02 |
P/B | 1.45 |
Price/FCF | NM |
EV/R | 19.35 |
EV/Ebitda | NM |
PEG | NM |
Lexicon Pharmaceuticals Inc (LXRX) share price today is $0.7147
Yes, Indians can buy shares of Lexicon Pharmaceuticals Inc (LXRX) on Vested. To buy Lexicon Pharmaceuticals Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in LXRX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Lexicon Pharmaceuticals Inc (LXRX) via the Vested app. You can start investing in Lexicon Pharmaceuticals Inc (LXRX) with a minimum investment of $1.
You can invest in shares of Lexicon Pharmaceuticals Inc (LXRX) via Vested in three simple steps:
The 52-week high price of Lexicon Pharmaceuticals Inc (LXRX) is $3.73. The 52-week low price of Lexicon Pharmaceuticals Inc (LXRX) is $0.62.
The price-to-earnings (P/E) ratio of Lexicon Pharmaceuticals Inc (LXRX) is
The price-to-book (P/B) ratio of Lexicon Pharmaceuticals Inc (LXRX) is 1.45
The dividend yield of Lexicon Pharmaceuticals Inc (LXRX) is 0.00%
The market capitalization of Lexicon Pharmaceuticals Inc (LXRX) is $244.80M
The stock symbol (or ticker) of Lexicon Pharmaceuticals Inc is LXRX